HLA-A and neoplasm: Taken together, dsSCD can be manufactured matching all six allotypic HLA-A,B,C molecules of an individual tumor patient, can be used as a high-throughput screening platform for allotype-specific peptide ligand validation and for pMHC-I multimer-guided scRNA-Seq for comprehensive TCR discovery combined with immune cell phenotyping.